Discovery and biological evaluation of novel cyanoguanidine P2X7 antagonists with analgesic activity in a rat model of neuropathic pain

Journal of Medicinal Chemistry

Volumn 52, Issue 10, 2009, Pages 3366-3376

  Perez Medrano, Arturo ^a   Donnelly Roberts, Diana L ^a   Honore, Prisca ^a   Hsieh, Gin C ^a   Namovic, Marian T ^a   Peddi, Sridhar ^a   Shuai, Qi ^a   Wang, Ying ^a   Faltynek, Connie R ^a   Jarvis, Michael F ^a   Carroll, William A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1,3 BENZODIOXOL 5 YL) N [1 [[[(CYANOIMINO)(2 METHYLPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL]ACETAMIDE; 2 (4 CHLOROPHENYL) N [1 [[[(CYANOIMINO)(2 METHYL 3 PYRIDINYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL]ACETAMIDE; 2 (4 CHLOROPHENYL) N [1 [[[(CYANOIMINO)(2 METHYLPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL]ACETAMIDE; 2 (4 CHLOROPHENYL) N [1 [[CYANOIMINO(5 QUINOLINYLAMINO)METHYL]AMINO] 2,2 DIMETHYLPROPYL]ACETAMIDE; ANALGESIC AGENT; GUANIDINE DERIVATIVE; N [1 [[(CYANOIMINO)(5 QUINOLINYLAMINO)METHYL]AMINO] 2,2 DIMETHYLPROPYL] 2 (2,3 DIHYDRO 1,4 BENZODIOXIN 6 YL)ACETAMIDE; N [1 [[(CYANOIMINO)(5 QUINOLINYLAMINO)METHYL]AMINO] 2,2 DIMETHYLPROPYL] 2 (3,4 DIMETHOXYPHENYL)ACETAMIDE; N [1 [[(CYANOIMINO)(5 QUINOLINYLAMINO)METHYL]AMINO] 2,2 DIMETHYLPROPYL] 2 [4 (METHYLTHIO)PHENYL]ACETAMIDE; N [1 [[(CYANOIMINO)(8 QUINOLINYLAMINO)METHYL]AMINO] 2,2 DIMETHYLPROPYL] 2 (3,4 DIMETHOXYPHENYL)ACETAMIDE; N [1 [[[(CYANOIMINO)(2 METHYL 3 PYRIDINYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 2 (3 FLUORO 4 METHYLPHENYL)ACETAMIDE; N [1 [[[(CYANOIMINO)(2 METHYL 3 PYRIDINYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 2 (4 FLUOROPHENYL)ACETAMIDE; N [1 [[[(CYANOIMINO)(2 METHYL 3 PYRIDINYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 2 [4 (METHYLTHIO)PHENYL]ACETAMIDE; N [1 [[[(CYANOIMINO)(2 METHYL 3 PYRIDINYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 4 (4 METHOXYPHENYL)BUTANAMIDE; N [1 [[[(CYANOIMINO)(2 METHYL 3 PYRIDINYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 5 PHENYLPENTANAMIDE; N [1 [[[(CYANOIMINO)(2 METHYLPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 2 (3,4 DIMETHOXYPHENYL)ACETAMIDE; N [1 [[[(CYANOIMINO)(2 METHYLPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 2 (3,5 DIMETHOXYPHENYL)ACETAMIDE; N [1 [[[(CYANOIMINO)(2 METHYLPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 2 (4 METHOXYPHENYL)ACETAMIDE; N [1 [[[(CYANOIMINO)(2 METHYLPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 2 (PHENYL)ACETAMIDE; N [1 [[[(CYANOIMINO)(2 METHYLPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 2 [4 (METHYLTHIO)PHENYL]ACETAMIDE; N [1 [[[(CYANOIMINO)(2 METHYLPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 3 (3,4 DIMETHOXYPHENYL)PROPANAMID; N [1 [[[(CYANOIMINO)(2 METHYLPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 3 (4 METHOXYPHENYL)PROPANAMIDE; N [1 [[[(CYANOIMINO)(2 METHYLPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 3,4 DIMETHOXYBENZAMIDE; N [1 [[[(CYANOIMINO)(2 METHYLPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 3,5 DIMETHOXYBENZAMIDE; N [1 [[[(CYANOIMINO)(2 METHYLPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 4 (4 METHOXYPHENYL)BUTANAMIDE; N [1 [[[(CYANOIMINO)(2 METHYLPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 4 METHOXYBENZAMIDE; N [1 [[[(CYANOIMINO)(2 METHYLPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 4 PHENYLBUTANAMIDE; N [1 [[[(CYANOIMINO)(2 METHYLPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL]HEXANAMIDE; N [1 [[[(CYANOIMINO)(3 FLUOROPHENYL)AMINO]METHYL]AMINO] 2,2 DIMETHYLPROPYL] 2 (3,4 DIMETHOXYPHENYL)ACETAMIDE; PURINERGIC P2X7 RECEPTOR; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; HUMAN CELL; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANALGESICS; ANIMALS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; DRUG DESIGN; DRUG DISCOVERY; GUANIDINES; INHIBITORY CONCENTRATION 50; NEURALGIA; PAIN; RATS; RECEPTORS, PURINERGIC P2; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 66249113481     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8015848     Document Type: Article

References (42)

1. Dubyak, G. R.; El-Moatassim, C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am. J. Physiol. 1993, 265, C577-C606.
2. Khakh, B.; Burnstock, G.; Kennedy, C.; King, B. F.; North, R. A.; Seguela, P.; Voigt, M.; Humphrey, P. P. A. International Union of Pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharm. Rev. 2001, 53, 107-118. (Pubitemid 32173110)
3. Burnstock, G.; Wood, J. N. Purinergic Receptors - their role in nociception and primary afferent neurotransmission. Curr. Opin Neurobiol. 1996, 6, 526-532. (Pubitemid 26313056)
4. Cook, S. P.; Vulchanova, L.; Hargreaves, K. M.; Elde, R.; McCleskey, E. W. Distinct ATP receptors on pain-sensing and stretch-sensing neurons. Nature 1997, 387, 505-508. (Pubitemid 27235468)
5. Jacobson, K. A.; Jarvis, M. F.; Williams, M. Purine and Pyrimidine (P2) Receptors as Drug Targets. J. Med. Chem. 2002, 45, 4057-4093.
6. 7 receptor: a pivotal role in inflammation and immunomodulation. Drug. Dev. Res. 1998, 45, 207-213.
7. Boarder, M. R.; Hourani, S. M. The regulation of vascular function by P2 receptors: multiple sites and multiple receptors. Trends Pharmacol. Sci. 1998, 19, 99-107. (Pubitemid 28197811)
8. Burnstock, G. Purinergic signaling and vascular cell proliferation and death. Arterioscler., Thromb. Vasc. Biol. 2002, 22, 364-373. (Pubitemid 34218740)
9. Bianchi, B. R.; Lynch, K. J.; Touma, E.; Niforatos, W.; Burgard, E. C.; Alexander, K. M.; Park, H. S.; Yu, Haixia, Metzger, R.; Kowaluk, E.; Jarvis, M. F; van Biesen, T. Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur. J. Pharmacol. 1999, 376, 127-138. (Pubitemid 29320178)
10. Jacobson, K. A.; Fischer, B.; Maillard, M.; Boyer, J, L.; Hoyle, C. H. V.; Harden, T. K.; Burnstock, G. Novel ATP agonists reveal receptor heterogeneity within P2X and P2Y subtypes. In Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology; Belardinelli, L., Pelleg, A., Eds.; Kluwer: Boston, 1995, pp 149-166.
11. 7 receptor of microglial cells: a novel immunomodullatory receptor. Prog. Brain Res. 1999, 120, 355-368.
12. 7 receptors. Am. J. Physiol. 2000, 279, C1189-C1197.
13. Burnstock, G. Overview of P2 receptors: possible functions in immune cells. Drug. Dev. Res. 2001, 53, 53-59. (Pubitemid 32845842)
14. 7 Receptors Are Targeted to Presynaptic Terminals in the Central and Peripheral Nervous Systems. J. Neurosci. 2001, 21, 7143-7152.
15. (a) Ferrari, D.; Chiozzi, P.; Falzoni, S.; Dal Susino, M.; Melchiorri, L.; Baricordi, O. R.; Di Virgilio, F. Extracellular ATP triggers IL-1β release by activating the purinergic P2Z receptor of human macrophages. J. Immunol. 1997, 159, 1451-1458. (Pubitemid 127484125)
16. (b) Ferrari, D.; Chiozzi, P.; Falzoni, S.; Hanau, S.; Di Virgilio, F. Purinergic modulation of interleukin-1β release from microglial cells stimulated with bacterial endotoxin. J. Exp. Med. 1997, 185, 579-582. (Pubitemid 27078376)
17. 7 receptor alters leukocyte function and attenuates an inflammatory response. J. Immunol. 2002, 168, 6436-6445.
18. 7 purinoceptor gene abolishes chronic inflammatory, and neuropathic pain. Pain 2005, 114, 386-396.
19. 7 like channels in cultured mouse astrocytes. Drug Dev. Res. 2000, 50, 92.
20. Carlton, S. M. Peripheral excitatory amino acids. Curr. Opin. Pharmacol. 2001, 1, 52-56. (Pubitemid 33585957)
21. 7 receptors in non-neuronal cells of rat dorsal root ganglia. Brain Res. 2005, 1052, 63-70.
22. (b) Duan, S.; Neary, J. T. P2X(7) receptors: properties and relevance to CNS function. Glia 2006, 54, 738-746. (Pubitemid 44629636)
23. 7 Receptor Expression in Rodent Brain. J. Neurosci. 2004, 24, 6307-6314.
24. 7 receptor function and immunoreactivity in neurons. Trends Neurosci. 2006, 29, 257-262.
25. Drug Treatment of Neuropathic Pain, Drug Ther. Bull. 2000, 38, 89-93.
26. Gargett, C. E.; Wiley, J. S. The isoquinoline derivative KN-62: A potent antagonist of the P2Z receptor of human lymphocytes. Br. J. Pharmacol. 1997, 120, 1483-1490. (Pubitemid 27192439)
27. 7 receptor antagonists: tyrosyl derivatives synthesized using a sequential parallel synthetic approach. Drug. Dev. Res. 2001, 54, 75-87.
28. 7 receptor. J. Med. Chem. 2003, 46, 1318-1329.
29. 7 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 4047-4050.
30. 7 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 4043-4047.
31. Nelson, D. W.; Gregg, R. J.; Kort, M. E.; Perez-Medrano, A.; Voight, E. A.; Wang, Y.; Grayson, G.; Namovic, M. T.; Donnelly-Roberts, D. L.; Niforatos, W.; Honore, P.; Jarvis, M. F.; Faltynek, C. R.; Carroll, W. A. Structure - Activity Relationship Studies on a Series of Novel, Substituted 1-Benzyl-5-phenyltetrazole P2X7 Antagonists. J. Med. Chem. 2006, 49, 3659-3666. (Pubitemid 43902471)
32. Wu, M. T. Synthesis of Some N,1- and N′,1-Diary-1H-1,2,4-triazole- 3,5-diamines. J. Heterocycl. Chem. 1977, 13, 443-444.
33. De Buyck, L.; Verhe, R.; De Kimpe, N.; Courtheyn, D.; Schamp, N. 2,2-Dichloroaldehydes from aldehydes and alcohols by chlorination in dimethylformamide. Bull. Soc. Chim. Belg. 1980, 89, 441-458.
34. Katritzky, A. R.; Drewniak, M. The Chemistry of Benzotriazole. Part 8. A Novel Two-Step Procedure for the N-alkylation of Amides. J. Chem. Soc., Perkin Trans. 1. 1988, 2339-2344.
35. Perez-Medrano, A.; Buckner, S. A.; Coghlan, M. J.; Gregg, R. J.; Gopalakrishnan, M.; Kort, M. E.; Lynch, J. K.; Scott, V. E.; Sullivan, J. P.; Whiteaker, K. L.; Carroll, W. A. Design and Synthesis of Novel Cyanoguanidine ATP-Sensitive Potassium Channel Openers for the Treatment of Overactive Bladder. Bioorg. Med. Chem. Lett. 2004, 14, 397-400. (Pubitemid 38045131)
36. Perez-Medrano, A.; Brune, M. E.; Buckner, S. A.; Coghlan, M. J; Fey, T. F.; Gopalakrishnan, M.; Gregg, R. J.; Kort, M. E.; Scott, V. E.; Sullivan, J. P.; Whiteaker, K. L.; Carroll, W. A. Structure - Activity Studies of Novel Cyanoguanidine ATP-Sensitive Potassium Channel Openers for the Treatment of Overactive Bladder. J. Med. Chem. 2007, 50, 6265-6273.
37. 7. Cloning and expression of a human cDNA. J. Biol. Chem. 1997, 272, 5482-5486.
38. 7R)-induced pore formation in human THP-1 cells. J. Pharmacol. Exp. Ther. 2004, 308, 1053-1061.
39. Kim, S. H.; Chung, J. M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992, 50, 355-363.
40. 7 Receptor Antagonist, Dose-Dependently Reduces Neuropathic Pain in the Rat. J. Pharmacol. Exp. Ther. 2006, 319, 1376-1385.
41. Tilley, Jefferson, W.; Ramuz, H.; Levitan, P.; Blount, John, F. The synthesis of 3,5-diamino-1,2,4-oxadiazoles. Part 2. Helv. Chim. Acta 1980, 63, 841-859.
42. 2,3-Dihydro-1,4-benzodioxin-6-ylacetic acid was prepared according to Vazquez, M. T.; Rosell, G.; Pujol, M. D. Synthesis and antiinflammatory activity of 2,3-dihydro-1,4-benzodioxin methylcarboxylic acids. Farmaco 1996, 51, 215-217.